- Home
- BFRI vs KPRX Comparison
BFRI vs KPRX Comparison
Compare BFRI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | KPRX |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | 94 | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 10.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BFRI | KPRX |
|---|---|---|
| Price | $0.99 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.75 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 168.5K | 28.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.36 | N/A |
| Revenue Next Year | $16.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.76 |
| 52 Week High | $1.19 | $3.29 |
Technical Indicators
Market Signals| Indicator | BFRI | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 47.12 |
| Support Level | $0.75 | $2.49 |
| Resistance Level | $1.06 | $2.91 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 70.03 | 19.05 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.